IMV's vaccine candidate potentially effective against COVID-19

 

• IMV (NASDAQ:IMV) rises 16% premarket after providing an update on the development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection.
• The Company has successfully completed preclinical safety, GLP toxicology as well as immunogenicity and challenge studies confirming a favorable safety profile and potential for the long duration of antibody titers and protection against SARS-CoV-2.
• Additional supporting evidence favoring DPX-COVID-19 includes T cell response and “natural” immunity in convalescent plasma against the targeted epitope peptides in the DPX-COVID-19 formulation.
• Vaccine candidate is stable at 2°C to 8°C and room temperature for at least 3 months.
• IMV has collaborated with a global manufacturing partner and initiated transfer and scale-up activities of DPX-COVID-19 in India and Europe to produce several hundred million doses.
• The Company is planning to conduct complementary preclinical studies including testing on new variants and will provide an update in Q1 2021 on its revised clinical plan.
• https://seekingalpha.com/news/3647476-imvs-vaccine-candidate-potentially-effective-against-covidminus-19-shares-up-16